Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.

Naoko Shigeta Shuji MurakamiTomoyuki YokoseTetsuya Isaka Kanako ShinadaTakuya NagashimaHiroyuki AdachiShunsuke ShigefukuKotaro MurakamiJun MiuraNoritake KikunishiKozue WatabeHaruhiro SaitoHiroyuki Ito

Published in: Thoracic cancer (2024)

This study showed a high concordance of PD-L1 expression with the SP263 and 22C3 assays. Further studies examining the therapeutic effects of adjuvant atezolizumab are required.

Keyphrases

high throughput
early stage
lymph node